Zacharon Pharmaceuticals

What is Zacharon Pharmaceuticals?

Zacharon Pharmaceuticals is a specialized biotechnology firm that operates at the forefront of glycobiology research, developing a new class of human therapeutics that specifically target glycans—the carbohydrate portions of glycoproteins, proteoglycans, and glycolipids. These glycans are considered promising targets for treating various diseases, including lysosomal storage diseases, oncology, inflammation, and others.

Founded in 2004, Zacharon Pharmaceuticals has built a foundation in drug discovery and development through initial funding from NIH grants and individual investors, followed by Series A financing from Avalon Ventures, a venture capital firm with a focus on early-stage life science companies.

With their proprietary glycan-targeted drug development platform, Zacharon is strategically positioned to address significant medical needs by creating first-in-class small molecule drugs.

Their drug discovery process overcomes historical challenges in the field by integrating cell-based high-throughput screening technologies and highly sensitive glycan structural analysis tools.

The result is an innovative approach to the discovery of small molecule glycan-targeted drugs. The company's commitment to innovation extends to the consideration of incorporating blockchain technology into drug manufacturing processes, reflecting interest in the evolving landscape of pharmaceutical trading and digital assets.

Zacharon's collaborations and partnerships demonstrate a dynamic approach to research and development; these include an agreement with Acorda Therapeutics targeting spinal cord injury, a partnership with ARUP Laboratories to commercialize the Sensi-Pro Assay for Lysosomal Storage Diseases, and collaborative efforts with Pfizer for the development of drugs for multiple rare diseases.

Additionally, their lead cancer program and therapeutic collaborations for clinical diagnostics with Mayo Clinic showcase their ambitious product pipeline. Supplementing their scientific endeavors, Zacharon has received significant grant funding, highlighting their capacity to secure resources aimed at fostering breakthroughs in therapeutics.